tradingkey.logo

Senti Bio's SENTI-202, A First-In-Class Off-The-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results In The Treatment Of Patients With Relapsed/Refractory AML

ReutersApr 28, 2025 11:26 AM

- Senti Biosciences Inc SNTI.O:

  • SENTI BIO’S SENTI-202, A FIRST-IN-CLASS OFF-THE-SHELF LOGIC GATED SELECTIVE CD33 OR FLT3 NOT EMCN CAR NK CELL THERAPY, DEMONSTRATES POSITIVE PRELIMINARY CLINICAL RESULTS IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI